Solid Biosciences

General Information
Business:

Our mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys; symptoms usually manifest between ages 3-5. DMD is a progressive, irreversible and ultimately fatal disease that affects about one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. DMD is caused by mutations in the dystrophin gene, which result in the absence or near absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and tear. Our lead product candidate is a gene-transfer candidate.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 58
Founded: 2013
Contact Information
Address 161 First Street, Third Floor, Cambridge, MA 02142, US
Phone Number (617) 337-4680
Web Address http://www.solidbio.com
View Prospectus: Solid Biosciences
Financial Information
Market Cap $546.4mil
Revenues $0 mil (last 12 months)
Net Income $-29.5 mil (last 12 months)
IPO Profile
Symbol SLDB
Exchange NASDAQ
Shares (millions): 7.8
Price range $16.00 - $16.00
Est. $ Volume $125.0 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Leerink Partners
CO-Managers Nomura/ Chardan
Expected To Trade: 1/26/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change